Follicular Lymphoma Clinical Trials in Milwaukee, Wisconsin

10 studies are recruiting for follicular lymphoma in Milwaukee, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

   The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   46 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07226843 on ClinicalTrials.gov

2. LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

   This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

   Stage

   Phase 1

   Ages

   18 to 81

   Site

   Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT05990465 on ClinicalTrials.gov

3. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital of Wisconsin, Milwaukee, Wisconsin

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

4. Epcoritamab and Rituximab for First-line Follicular Lymphoma

   The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   6 in total

   Run by

   Reid Merryman, MD

   See if you can join NCT05783609 on ClinicalTrials.gov

5. CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

   This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adu…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT04186520 on ClinicalTrials.gov

6. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

7. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

8. Long-term Follow-up Study of Patients Receiving CAR-T Cells

   This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT03375619 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Milwaukee, Wisconsin

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

10. A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

    The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

    Stage

    Not phased

    Ages

    18 and older

    Site

    CIBMTR, Milwaukee, Wisconsin

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06794268 on ClinicalTrials.gov